Antimicrobial susceptibility of Helicobacter pylori strains isolated in Colombia

Helicobacter pylori antimicrobial resistance rates differ among countries and even between different areas of a country. In Colombia, the most commonly used antimicrobials for the treatment of H pylori infection are amoxicillin, clarithromycin and metronidazole. To determine antimicrobial susceptibi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revista medíca de Chile 2009-10, Vol.137 (10), p.1309-1314
Hauptverfasser: Alvarez, Adalucy, Moncayo, José Ignacio, Santacruz, Jorge Javier, Corredor, Luisa Fernanda, Reinosa, Elizabeth, Martínez, José William, Beltrán, Leonardo
Format: Artikel
Sprache:spa
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Helicobacter pylori antimicrobial resistance rates differ among countries and even between different areas of a country. In Colombia, the most commonly used antimicrobials for the treatment of H pylori infection are amoxicillin, clarithromycin and metronidazole. To determine antimicrobial susceptibility of H pylori strains isolated in Colombia. Eighty eight strains of H pylori were isolated and identified by microbiological methods and confirmed with polymerase chain reaction (PCR). The detection of antimicrobial resistance to amoxicillin, clarithromycin, metronidazole and tetraclycline, was conducted by the Etest method. Mutations in the 23S rDNA, involved in resistance to clarithromycin, were detected using PCR and restriction fragment length polymorphism. Eighty eight and 2.2% of the strains were resistant to metronidazole and clarithromycin, respectively. No isolate was simultaneously resistant to amoxicillin or tetracycline. The two clarithromycin resistant strains were homozygous for the A2143G mutation. No mutations were found in the remaining 86 susceptible strains. The high rate of metronidazole resistance in our population precludes the use of this drug for the empirical treatment of H pylori infection.
ISSN:0034-9887
DOI:10.4067/S0034-98872009001000005